{
    "pmcid": "11108896",
    "qa_pairs": {
        "How do nanobodies contribute to the neutralization of SARS-CoV-2 according to the paper?": [
            "They target the spike protein, preventing viral entry into host cells.",
            "They bind to the nucleocapsid protein, inhibiting viral replication.",
            "They disrupt the viral RNA polymerase, halting viral transcription.",
            "They interfere with the viral lipid membrane, causing viral lysis."
        ],
        "What are the origins of nanobodies as described in the paper?": [
            "Nanobodies are derived from the heavy-chain antibodies found in camelids and sharks.",
            "Nanobodies are synthesized from human monoclonal antibodies.",
            "Nanobodies originate from bacterial immune systems.",
            "Nanobodies are engineered from plant-based proteins."
        ],
        "What is a potential future direction for nanobody research highlighted in the paper?": [
            "Development of broad-spectrum antivirals targeting multiple viral variants.",
            "Creation of nanobodies that can self-replicate in host cells.",
            "Design of nanobodies that can be administered orally.",
            "Engineering nanobodies to function as vaccines."
        ],
        "What is a strategy mentioned in the paper to prolong the half-life of nanobodies?": [
            "Conjugation with serum albumin.",
            "Increasing their molecular weight.",
            "Reducing their binding affinity.",
            "Enhancing their solubility."
        ],
        "What is one of the main challenges associated with the use of nanobodies in therapeutic applications?": [
            "Their short half-life due to rapid clearance from the bloodstream.",
            "Their high immunogenicity leading to adverse immune responses.",
            "Their inability to penetrate tissue effectively.",
            "Their instability in various expression systems."
        ]
    }
}